Drug Trial Radar · NCT07136987
A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery
Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,104
Planned (sponsor's estimate)
Start
Jan 2026
Primary completion
Jan 2031
Study completion Jul 2031
Sponsor
- Lead sponsor
- Open Source Pharma FoundationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute for Research in Tuberculosis, Chennai, India
- First posted
- Aug 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tuberculosis is a leading global cause of morbidity and mortality. Even if cured, a majority patients are left with bronchiectasis and fibrosis, permanent conditions that impair lung function. Large cohort studies have confirmed that even modest loss of lung function is associated with excess mortality risk. This study will examine if two treatments, metformin and N-acetylcysteine (NAC), can promote the recovery of lung function in TB if given together with standard TB treatment. There currently are no drugs approved for this indication.
Conditions
- Tuberculosis
Interventions
MetforminDrug
Metformin 500 mg QAM x 1 wk, then 500 mg BID x 1 wk, then 1000 mg QAM and 500 mg QPM, plus standard TB treatment
N-Acetylcysteine (NAC) TreatmentDietary supplement
N-acetylcysteine (NAC) 1800 mg orally twice daily plus standard TB treatment
Standard TB treatmentCombination product
Standard TB treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- FEV1Time frame: month 18
- Favourable treatment outcomeTime frame: 18 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.